|
|
News Breaks | | | | November 9, 2012 | | 17:07 EDT |  | CELG | Celgene study shows ABRAXANE improves survival for pancreatic cancer patients
Celgene International Sarl, a subsidiary of Celgene Corporation, announced that its phase III study of ABRAXANE, a paclitaxel protein-bound particles for injectable suspension, in combination with gemcitabine in treatment-naive patients with advanced pancreatic cancer met its primary endpoint of overall survival. In the study, ABRAXANE in combination with gemcitabine demonstrated a statistically significant improvement in overall survival compared to patients receiving gemcitabine alone. The primary endpoint for the study is improvement in overall survival. Secondary endpoints include evaluation of progression-free survival, objective tumor response and the safety and tolerability of this combination in this patient population. The safety profile of ABRAXANE in combination with gemcitabine observed in the study is comparable with other ABRAXANE clinical trials in pancreatic cancer. Based on the results of the MPACT study, the company plans to submit dossiers for registration in the US, Europe and other markets. ABRAXANE is not currently approved for the treatment of advanced pancreatic cancer. | |
|
News For CELG From The Last 14 Days Check below for free stories on CELG the last two weeks. |
|
|
| May 20, 2013 | | 09:51 EDT |  | CELG | Celgene management to meet with JPMorgan
Meetings to be held in Boston on May 22-23 hosted by JPMorgan. | | | May 17, 2013 | | 05:51 EDT |  | CELG | Stocks with implied volatility movement; CBST CELG
 Subscribe for More Information | | | May 16, 2013 | | 11:50 EDT | | CELG | Celgene, Gilead lower after new data published at ASCO
Subscribe for More Information | | | May 7, 2013 | | 07:18 EDT |  | CELG | Barclays has increased confidence in Celgene's re-filing of Revlimid
Subscribe for More Information | |
|
|
|
|
|
|
